

1 **Title: Human bronchopulmonary disposition and plasma pharmacokinetics of oral**
2 **bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19**

3

4 Authors:

5 Xiao-Jian Zhou,^{a,#} Arantxa Horga,^a Adeep Puri,^b Lee Winchester,^c Maureen Montrond,^a Keith
6 Pietropaolo,^a Bruce Belanger,^a Courtney V. Fletcher,^c Janet Hammond^a

7

8 Affiliations:

9 ^aAtea Pharmaceuticals, Inc., Boston, Massachusetts, USA

10 ^bHammersmith Medicines Research Ltd, London, UK

11 ^cAntiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha,
12 Nebraska, USA

13

14 Running title: Human lung disposition and plasma PK of bemnifosbuvir

15

16 [#]Address correspondence to Xiao-Jian Zhou, zhou.xj@ateapharma.com

17 **ABSTRACT**

18 Bemnifosbuvir (BEM, AT-527) is a novel oral guanosine nucleotide antiviral drug for the
19 treatment of patients with COVID-19. Direct assessment of drug disposition in the lungs, via
20 bronchoalveolar lavage, is necessary to ensure antiviral drug levels at the primary site of
21 SARS-CoV-2 infection are achieved. We conducted a Phase 1 study in healthy subjects to
22 assess the bronchopulmonary pharmacokinetics, safety, and tolerability of repeated doses
23 of BEM. A total of 24 subjects were assigned to receive twice-daily (BID) BEM at doses of
24 275, 550, or 825 mg for up to 3.5 days. AT-511, the free base of BEM, was largely eliminated
25 from the plasma within 6 h post dose in all dosing groups. Antiviral drug levels of BEM were
26 consistently achieved in the lungs with BEM 550 mg BID. The mean level of the guanosine
27 nucleoside metabolite AT-273, the surrogate of the active triphosphate metabolite of the
28 drug, measured in the epithelial lining fluid of the lungs was 0.62 μM at 4–5 h post dose.
29 This exceeded the target *in vitro* 90% effective concentration (EC_{90}) of 0.5 μM for antiviral
30 drug exposure against SARS-CoV-2 replication in human airway epithelial cells. BEM was
31 well tolerated across all doses tested, and most treatment-emergent adverse events
32 reported were mild in severity and resolved. The favorable pharmacokinetics and safety
33 profile of BEM demonstrates its potential as an oral antiviral treatment for COVID-19, with
34 550 mg BEM BID currently under further clinical evaluation in patients with COVID-19.

35

36 INTRODUCTION

37 The COVID-19 pandemic caused by SARS-CoV-2 continues to be a worldwide public-health
38 concern, with more than 6.9 million confirmed deaths reported globally according to the
39 World Health Organization ([https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)
40 [2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)). SARS-CoV-2 infects the respiratory tract and, although the nasopharynx is an initial
41 portal of entry and site of infection commonly used in testing, it is infection of the lower
42 airway and lungs that results in substantial mortality (1-4). Effective drug delivery to the
43 critical site of infection and prevention of disease progression is therefore important for the
44 treatment of COVID-19. Currently, remdesivir and nirmatrelvir/ritonavir are the only
45 antiviral drugs approved by the FDA for the treatment of COVID-19, and molnupiravir has
46 received emergency use authorization by the FDA ([https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19)
47 [events/press-announcements/fda-approves-first-treatment-covid-19;](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19)
48 [https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults)
49 [treatment-covid-19-adults;](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults) [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain)
50 [events/press-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain)
51 [announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain)
52 [treatment-covid-19-certain](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain)). However, remdesivir is not suitable for oral delivery due to its
53 rapid clearance, and is limited to use in a hospital or alike setting due to intravenous
54 infusion as the only route of administration (5-7). Many drug–drug interactions between
55 nirmatrelvir/ritonavir and concomitant medications have been identified in patients with
56 COVID-19 (8-11). Furthermore, uncertainties regarding the mutagenicity of molnupiravir
57 towards mammalian host DNA have been reported, as well as evidence of molnupiravir-
58 induced mutations in the virus sequence which could potentially lead to new variants of
SARS-CoV-2 (12-16). Although the pharmacokinetics (PK) of these antiviral drugs against


59 SARS-CoV-2 have previously been studied (17-19), there is a lack of clinical data regarding
60 the attainment of antiviral drug levels in the lungs, the site of SARS-CoV-2 replication, which
61 can be measured by bronchoalveolar lavage (BAL). Despite the high viral load of SARS-CoV-2
62 in the lung tissue, data suggest that repurposed antiviral drugs used to treat COVID-19 may
63 not reach an effective concentration in the lungs necessary to inhibit viral replication (20,
64 21). Hence, there is an unmet need for direct-acting antivirals that can be widely
65 administered in an outpatient setting and are demonstrated to effectively target the
66 primary site of infection.

67 Bemnifosbuvir (BEM, AT-527) is an orally available guanosine nucleotide prodrug that has
68 demonstrated potent antiviral activity against hepatitis C virus (HCV) and SARS-CoV-2 (22-
69 24). BEM is the hemisulfate salt of AT-511, a novel phosphoramidate prodrug that is
70 converted after multistep activation to the active 5' triphosphate metabolite AT-9010,
71 which is formed only after intracellular delivery of the prodrug (**Figure 1**) (23, 24). AT-9010
72 selectively inhibits viral replication by a dual mechanism of action, simultaneously targeting
73 the RNA-dependent RNA polymerase (RdRp) and nidovirus RdRp-associated nucleotidyl
74 transferase (NiRAN) domains of the SARS-CoV-2 RNA polymerase, resulting in potent
75 inhibition of viral RNA synthesis (25). Dephosphorylation of AT-9010 results in the formation
76 of the guanosine nucleoside metabolite AT-273, which is regarded as a surrogate plasma
77 marker for intracellular concentrations of AT-9010 (24).

78 Once daily (QD) dosing of BEM up to 550 mg in healthy volunteers and HCV-infected
79 patients has previously been assessed in two clinical trials (ClinicalTrials registration no.
80 NCT03219957; ClinicalTrials registration no. NCT04019717). Although the human PK profile
81 reported for BEM in HCV-infected patients is also likely to be observed in patients with

82 COVID-19, epithelial lining fluid (ELF) and the alveolar macrophages (AM) that reside in the
83 ELF are important sites of infection in COVID-19, and therefore information about drug
84 concentrations in the extracellular and intracellular compartments of the lung is essential
85 for development of a drug targeting lower respiratory tract infections.
86 This Phase 1 study was designed to evaluate antiviral drug levels of BEM in the lungs of
87 healthy volunteers using BAL to demonstrate attainment of antiviral drug levels at the
88 primary site of SARS-CoV-2 infection, and to assess the safety and tolerability of BEM when
89 given as repeated oral doses. Dosing of BEM was informed by the previously predicted lung
90 exposure of its active triphosphate metabolite AT-9010, using plasma levels of its surrogate
91 nucleoside metabolite AT-273, to exceed the *in vitro* 90% effective concentration (EC₉₀) of
92 0.5 μM BEM for inhibition of SARS-CoV-2 replication (24, 26). BEM 550 mg twice daily (BID)
93 was expected to produce sustained lung exposure to AT-9010 greater than the
94 concentration required to inhibit SARS-CoV-2 replication in human airway epithelial (HAE)
95 cells *in vitro* (24). Although the 550 mg BID regimen was believed to be optimal, a lower and
96 higher dose were also evaluated so that a dose-response relationship could be established.

97 **Figure 1. Activation pathway of BEM (AT-527).**



98

99 Circles indicate BEM structural features critical to its potent antiviral activity/lack of toxicity.

100 5'-NTase, 5'-nucleotidase; ADALP1, adenosine deaminase-like protein 1; BEM, bemnifosbuvir; CatA, cathepsin A; CES1,
101 carboxylesterase 1; GUK1, guanylate kinase 1; HINT1, histidine triad nucleotide binding protein 1; MP, monophosphate;
102 NDPK, nucleoside-diphosphate kinase.

103

104 RESULTS

105 Subject demographics and baseline characteristics

106 A total of 24 healthy subjects entered and completed the trial, and no subjects were
107 withdrawn. All enrolled subjects were included in the safety population, PK concentration
108 population, and PK parameter population. Demographics and baseline characteristics are
109 summarized in **Table 1**. The groups across dosing levels were generally comparable, with sex
110 being the only notable difference across dosing levels: one woman (12.5%) received 275 mg
111 BEM BID, while an equal number of men and women (four each per dose) received the
112 other dose levels (550 mg and 825 mg BID). There were no other notable demographic
113 differences between groups. No subjects identified their ethnicity as Hispanic or Latino.

114 **Table 1. Baseline characteristics of study subjects.**

Variable	275 mg BEM BID n=8	550 mg BEM BID n=8	825 mg BEM BID n=8	All subjects N=24
Mean age, years (range)	42.3 (23–64)	44.0 (27–62)	40.6 (21–64)	42.3 (21–64)
Female, n (%)	1 (12.5)	4 (50.0)	4 (50.0)	9 (37.5)
Male, n (%)	7 (87.5)	4 (50.0)	4 (50.0)	15 (62.5)
Race, n (%)				
Black or African American	0	0	2 (25.0)	2 (8.3)
White	8 (100.0)	8 (100.0)	5 (62.5)	21 (87.5)
Other	0	0	1 (12.5)	1 (4.2)
Mean weight, kg (range)	79.1 (67.2–96.4)	72.2 (56.4–94.5)	69.5 (56.6–83.3)	73.6 (56.4–96.4)
Mean BMI, kg/m ² (range)	24.4 (20.1–27.9)	25.2 (22.8–27.9)	23.8 (20.8–26.0)	24.5 (20.1–27.9)

115 BEM, bemnifosbuvir; BID, twice daily; BMI, body mass index.

116

117 **Safety and tolerability**


118 BEM was well tolerated across all doses, and no serious adverse events (SAEs) or adverse
119 events (AEs) leading to discontinuation were observed during the study. 11 subjects (45.8%)
120 reported at least one treatment-emergent adverse event (TEAE) after the start of BEM
121 dosing (17 reported in total). Of the 11 subjects reporting a TEAE, two subjects (25.0%) had
122 received 275 mg, three (37.5%) had received 550 mg, and six (75.0%) had received 825 mg
123 BEM BID. The most frequently reported TEAEs were nausea (n=2; 825 mg BEM BID),
124 esophageal mucosa erythema (n=2; 825 mg BEM BID), and oropharyngeal pain (n=2; one
125 each at 275 mg and 825 mg BEM BID). All other TEAEs were reported in one subject each
126 (dizziness, headache, lethargy, paresthesia, tremor, chest pain, pyrexia, vessel puncture site
127 bruise, increased C-reactive protein [CRP] and leukocyte count, and back pain). The severity
128 of most TEAEs was considered to be mild, except for three that were Grade 2 in severity
129 (headache, chest pain, and pyrexia), each reported by one subject per dosing level. Of the
130 17 TEAEs reported, two (both mild nausea) were considered to be possibly related to the
131 study drug, both after the second dose of 825 mg BEM BID and lasting 1–2 h. Three TEAEs
132 had unknown outcomes and were reported during subjects' final follow-up visit (lethargy
133 and two instances of esophageal mucosa erythema), and all other TEAEs resolved. One
134 subject who received 825 mg BEM BID reported a fever after the final dose, approximately 4
135 h after bronchoscopy, although this was likely a side effect of the midazolam sedation
136 medication used during bronchoscopy. The fever coincided with a high leukocyte count and
137 raised CRP level, which was considered clinically significant; however, the leukocyte count
138 was within the reference range at all other timepoints and the CRP level returned to normal
139 by the time of the subject's follow-up visit.

140 **Plasma PK**

141 Mean (\pm standard deviation [SD]) plasma concentration–time profiles for AT-511 and the
142 guanosine nucleoside metabolite AT-273 (surrogate of the intracellular active triphosphate
143 AT-9010) are presented in **Figure 2**. The mean AT-511 plasma concentration–time curves
144 were similar in shape after the last dose of 275 mg, 550 mg, and 825 mg BEM BID.
145 Plasma PK parameters of AT-511 and AT-273 are summarized in **Table 2**. AT-511 was rapidly
146 absorbed in plasma after oral dosing, with the rate of absorption unaffected by dose:
147 median time to maximum plasma concentration (t_{max}) was 0.5 h after all doses of BEM. AT-
148 511 was largely eliminated from plasma within 6 h post dose with a short half-life of
149 approximately 1 h in all dosing groups, and the concentration–time profile was consistent
150 with first-order PK. Mean maximum plasma concentration (C_{max}) and area under plasma
151 concentration–time curve during a dosing interval (AUC_{τ}) of AT-511 increased more than
152 proportionally at the lower dosing levels of 275 mg and 550 mg BEM BID, and less than
153 proportionally at the higher dosing levels of 550 mg and 825 mg BEM BID.

154

155 **Figure 2. Mean (\pm SD) plasma concentration–time profiles of AT-511 (A) and AT-273 (B) on**
156 **the last dosing day up to 12 h post dose of 275 mg, 550 mg, and 825 mg BEM dosage**
157 **regimens (inserts: semi-log plots with no SD for clarity).**



158

159 BEM, bemnifosbuvir; BID, twice daily; SD, standard deviation.

160 '0 h' is pre dose (morning), '4 h' is 4 h or pre BAL (4–5 h, as applicable), and '10 h' is pre BAL (11–12 h). Values below the

161 limit of quantification are imputed to 0.

162 Panel A: At each dose level, n=8 except at 10 h (n=4).

163 **Table 2. Summary of repeat dose plasma PK parameters of AT-511 and AT-273: PK**
 164 **parameter population.**

PK parameter		AT-511			AT-273		
		275 mg BEM BID (2.5 days)	550 mg BEM BID (2.5 days)	825 mg BEM BID (3.5 days)	275 mg BEM BID (2.5 days)	550 mg BEM BID (2.5 days)	825 mg BEM BID (3.5 days)
C _{max} (ng/mL)	Mean (± SD) ^a	415 (411)	2970 (2364)	3040 (1185)	142 (37.2)	285 (74.4)	313 (101)
	Median	0.50	0.50	0.50	3.00	3.00	4.00
t _{max} (h)	Range	0.50–1.00	0.50–2.00	0.50–1.00	0–4.00	0–6.17	0–4.10
	Mean (± SD) ^a	504 (647)	2695 (2061)	3306 (1451)	1354 (315)	2640 (731)	2935 (998)
t _{1/2} (h)	Mean (± SD) ^a	0.81 (0.27)	1.00 (0.19)	1.17 (0.36)	ND ^b	ND ^b	ND ^b

165 ^aArithmetic mean. ^bNot determined due to sampling time limited to dosing interval.

166 AUC_τ, area under the concentration–time curve (AUC) during a dosing interval; BEM, bemnifosbuvir; BID, twice daily; C_{max},
 167 maximum plasma concentration; PK, pharmacokinetic; SD, standard deviation; t_{1/2}, half-life; t_{max}, time to maximum plasma
 168 concentration.

169 N=8 for all dose levels.

170

171 After BEM BID, median t_{max} of AT-273 was 3–4 h across dose levels. Mean C_{max} and AUC_τ of
 172 AT-273 increased proportionally with dose. The mean (± SD) trough plasma concentrations
 173 (C_{trough}) of AT-273 at 12 h after the final dose of 275 mg, 550 mg, and 825 mg BEM BID were
 174 92.1 (27.2), 168.0 (51.8), and 144.7 (47.6) ng/mL, respectively. Plasma concentrations of AT-
 175 273 were sustained without much fluctuation and consistently exceeded the target level of
 176 150 ng/mL (0.5 μM, EC₉₀ of the drug for inhibiting SARS-CoV-2 replication in HAE cells *in*
 177 *vitro*) over the dose interval with BEM 550 mg BID (**Figure 2**).

178 **ELF and time-matched plasma concentrations**

179 Mean (± SD) ELF and time-matched plasma concentrations of AT-273 are presented in **Table**
 180 **3**. All AT-511 concentrations in ELF were below the limit of quantification (BLQ), except for
 181 one subject who had an AT-511 concentration of 10.5 ng/mL in ELF on Day 4, at the 4–5 h

182 BAL timepoint. Concentrations of AT-273 were quantifiable in BAL fluid supernatant (BALF)
 183 at the two highest dose levels of BEM (550 mg and 825 mg BID), regardless of BAL
 184 timepoint. After 275 mg BEM BID, three of four subjects who had their BAL at 11–12 h post
 185 dose had quantifiable AT-273 in BALF, but all four of those who had their BAL at 4–5 h post
 186 dose did not. Overall, ELF AT-273 concentrations were higher among subjects who had their
 187 BAL procedure at 4–5 h post dose than in those who had BAL at 11–12 h post dose,
 188 approximately corresponding to the peak and trough plasma levels.

189 **Table 3. Mean (\pm SD) comparative ELF vs plasma concentrations of AT-273.**

Dose	AT-273 concentration (ng/mL)	Sampling time (h)	
		Day 3 or 4 ^a 4–5 h	Day 3 or 4 ^a 11–12 h
275 mg BEM BID (2.5 days)	Mean ELF (\pm SD)	0	53.3 (44.2)
	Mean plasma (\pm SD)	117 (21.4)	92.1 (27.2)
	Ratio (\pm SD)	0	0.72 (0.10) ^b
550 mg BEM BID (2.5 days)	Mean ELF (\pm SD)	185 (89.6)	138 (76.0)
	Mean plasma (\pm SD)	240 (39.4)	168 (51.8)
	Ratio (\pm SD)	0.76 (0.30)	0.79 (0.18)
825 mg BEM BID (3.5 days)	Mean ELF (\pm SD)	197 (96.2)	103 (24.0)
	Mean plasma (\pm SD)	330 (110)	145 (47.6)
	Ratio (\pm SD)	0.58 (0.20)	0.73 (0.09)

190 ^aLast dosing day was on Day 3 for Groups 1 and 2 (275 and 550 mg BID) and on Day 4 for Group 3 (825 mg BID). ^bn=3.


191 BEM, bemnifosbuvir; BID, twice daily; ELF, epithelial lining fluid; SD, standard deviation.

192 0.5 μ M equivalent to 150 ng/mL for AT-273. Half of each cohort had the BAL procedure 4–5 h after dosing, the other half
 193 at 11–12 h after dosing. At each dose level, n=8 except at 11–12 h (n=4). ELF concentrations BLQ were imputed to 0 before
 194 correcting the values for (plasma/BALF) urea ratio.

195 At the 550 mg BEM BID dose, mean ELF levels of AT-273 at the 4–5 h and 11–12 h BAL
 196 timepoints were 185 and 138 ng/mL (0.62 and 0.46 μ M), respectively (exceeding or
 197 approaching the target level of 150 ng/mL or 0.5 μ M). Similarly, at the 825 mg BEM BID
 198 dose, mean ELF levels of AT-273 at the 4–5 h and 11–12 h BAL timepoints were 197 and 103

199 ng/mL (0.66 and 0.34 μ M), respectively. Mean ratios of ELF-to-plasma concentrations were
200 generally below 1 (range of 0.58 to 0.78). There was a significant correlation between ELF
201 and plasma levels of AT-273 ($r^2=0.6777$, $p<0.0001$) (**Figure 3**).

202 **Figure 3. Correlation between plasma and ELF AT-273 levels.**



203

204 BID, twice daily; ELF, epithelial lining fluid.

205 ELF AT-273 levels with 275 mg BID at the 4 h timepoint were BLQ and therefore excluded.

206 **AT-9010 concentrations**

207 AM samples for the 275 mg and 550 mg BEM BID doses were left at room temperature

208 without dry ice for 11 days (May 24 to June 4, 2021) during transfer, resulting in degradation

209 of AT-9010 and making data uninterpretable. After 825 mg BEM BID, AT-9010 in AM was

210 quantifiable (>lower limit of quantification [LLQ] at 3.34 fmol) in all but one subject who had

211 their BAL at 11–12 h post dose. In the remaining subjects, AT-9010 concentrations in AM
212 ranged from 0.79 to 5.37 nM.

213

214 **DISCUSSION**

215 The PK of orally administered BEM has previously been reported in HCV-infected patients,
216 and briefly described in healthy subjects and patients with COVID-19 (22, 26, 27); however,
217 the delivery to the lungs of BEM or any other direct-acting antivirals against SARS-CoV-2 has
218 not previously been studied. This study describes the first results of a Phase 1 study
219 assessing the intrapulmonary disposition and plasma PK of BEM following various doses in
220 healthy adults. BEM was well tolerated across all doses of 275, 550, and 825 mg BID tested
221 in healthy volunteers, with no clinically significant physical examination findings, vital signs,
222 or electrocardiogram (ECGs) observed. There were no deaths, non-fatal SAEs, nor other
223 significant AEs or AEs leading to subject withdrawal from treatment during the study. All
224 TEAEs reported were mild or moderate in severity. The overall rate of TEAEs reported
225 increased with increasing doses of BEM, with 25% of subjects reporting mild nausea after
226 825 mg BEM BID, which was considered as possibly related to the study drug. Two clinically
227 significant laboratory results were reported in one subject receiving 825 mg BEM BID (high
228 leukocyte count and raised CRP) coinciding with a fever; however, these symptoms were
229 considered likely a result of the midazolam sedation used during bronchoscopy. BEM was
230 well tolerated at the 550 mg BID dose, with no gastrointestinal TEAEs reported. This is
231 consistent with the favorable safety profile of 550 mg BEM previously observed in HCV-
232 infected subjects (22), the administration of 550 mg BEM QD in combination with
233 daclatasvir for up to 12 weeks (28), and 550 mg BID BEM for 5 days assessed in both

234 hospitalized patients with moderate COVID-19 and non-hospitalized patients with mild-to-
235 moderate COVID-19 (29, 30).

236 As designed, AT-511, a phosphoramidate prodrug, exhibited a very transient plasma profile
237 with fast absorption followed by rapid multistep activation to the intracellular antiviral
238 triphosphate AT-9010. The active triphosphate was then dephosphorylated to the
239 guanosine nucleoside metabolite, AT-273, which entered general circulation. As AT-273
240 cannot efficiently be anabolized to its phosphorylated forms, circulating AT-273 is therefore
241 considered a surrogate of AT-9010. Oral dosing of BEM 550 mg BID resulted in sustained
242 plasma levels of AT-273, which consistently exceeded the target of 150 ng/mL or 0.5 μ M,
243 the *in vitro* EC₉₀ of AT-511 for inhibiting SARS-CoV-2 replication in HAE cells.

244 The BAL samples were obtained at 4–5 h and 11–12 h post dose to capture the maximum
245 and trough ELF levels of AT-273. Due to its rapid clearance, AT-511 was not expected to be
246 frequently measurable at these timepoints in the BAL fractions. In fact, AT-511
247 concentrations in BAL samples were BLQ in all but one subject. By contrast, AT-273
248 concentrations were mostly quantifiable in BAL samples, especially with the 550 mg BID and
249 825 mg BID doses. The 275 mg BID dose, however, did not achieve sufficient AT-273 levels.

250 BEM 550 mg BID achieved ELF levels of AT-273, surrogate of AT-9010, exceeding or
251 approaching the target 150 ng/mL or 0.5 μ M at 4–5 h and 11–12 h, providing direct
252 evidence that BEM 550 mg BID produced antiviral drug exposure in the lungs and confirming
253 previously predicted lung AT-9010 levels with this regimen (24). The 825 mg BID regimen
254 also produced ELF AT-273 levels exceeding the target at 4–5 h, but increased less than dose-
255 proportionally from the 550 mg BID dose. ELF and plasma levels of AT-273 were found to be
256 significantly correlated, potentially allowing for prediction of ELF levels from plasma

257 samples, which are more commonly available. This relationship, taken together with
258 previous results showing that plasma levels of AT-273 rapidly increased to exceed the target
259 150 ng/mL within a few hours of the first dose of BEM 550 mg BID (26, 27), suggests that
260 BEM produced antiviral drug exposure in the lungs shortly following initiation of treatment.
261 Since direct-acting antivirals are most effective when administered during the early stage of
262 SARS-CoV-2 infection (7), high antiviral drug levels in the lungs achieved early after
263 administration of BEM 550 mg BID are of particular relevance to a better treatment
264 outcome. This is supported by the findings that BEM 550 mg BID for 5 days reduced
265 hospitalization rates in patients with COVID-19 by 71% compared with placebo (n=207)
266 (ClinicalTrials registration no. NCT04889040) (30).

267 In summary, the results of this study provide important information on the PK disposition of
268 oral BEM in the lungs of healthy subjects assessed by BAL, which is the primary site of SARS-
269 CoV-2 infection. We have confirmed the formation of AT-9010, the active triphosphate
270 metabolite of BEM, in alveolar macrophages and demonstrated that the dosing regimen of
271 550 mg BEM BID achieved the target antiviral drug exposure in the lungs of 0.5 μM EC₉₀
272 against SARS-CoV-2 replication, with a mean AT-273 ELF concentration of 0.62 μM at BAL
273 taken 4–5 h post dose, exceeding the target antiviral level. In addition to the favorable PK
274 demonstrated, BEM was well tolerated, with no significant AEs reported. BEM is therefore
275 an attractive antiviral treatment for COVID-19, and the oral route of administration allows
276 for use in the outpatient setting. A global Phase 3 clinical trial (ClinicalTrials registration no.
277 NCT05629962) is currently ongoing to evaluate the safety and efficacy of oral BEM 550 mg
278 BID for the treatment of high-risk outpatients with COVID-19.

279

280 **MATERIALS AND METHODS**

281 **Study design and subjects**

282 This was a Phase 1, open-label study to assess the bronchopulmonary PK, safety, and
283 tolerability of repeated doses of BEM in healthy subjects (ClinicalTrials.gov registration no.
284 NCT04877769). Healthy adult subjects between the ages of 18 and 65 who met the inclusion
285 and exclusion criteria were considered eligible for this study. All subjects were required to
286 have an initial screening that included clinical history, physical examination, 12-lead ECG,
287 vital signs, spirometry, and laboratory tests of blood and urine. A follow-up visit was
288 scheduled for 7 days after the last dose. All subjects were required to weigh at least 50 kg
289 and have a body mass index of between 18 and 29 kg/m², inclusive. Subjects were also
290 required to have a forced expiratory volume (FEV₁) and forced vital capacity (FVC) ≥80% of
291 predicted value and FEV₁/FVC ratio >0.7 within 28 days before their first dose of trial
292 medication. Exclusion criteria included clinically relevant abnormal medical history, physical
293 findings, ECG, or laboratory values at the pre-trial screening assessment; positive test for
294 SARS-CoV-2 or suspected exposure to the SARS-CoV-2 virus during the 14 days before
295 screening; receipt of a vaccine against COVID-19 in the 14 days before the first dose; or
296 scheduled to receive a dose of the vaccine 2 weeks after the last dose. Subjects could not
297 have received a prescription medicine during the 28 days before the first dose, and no over-
298 the-counter medicine or herbal or dietary supplements were permitted during the 7 days
299 before the first dose. Subjects with positive tests for hepatitis B antigen, hepatitis C, or
300 human immunodeficiency virus were excluded. Subjects were allocated to receive either
301 550 mg of BEM for 2.5 days (Group 1), 275 mg of BEM for 2.5 days (Group 2), or 825 mg

302 BEM for 3.5 days (Group 3), up to seven doses in total. Each dose was administered orally as
303 either one or three tablets and taken with approximately 240 mL water.

304 The study protocol was approved by the UK Medicines and Healthcare products Regulatory
305 Agency and West Midlands – Edgbaston Research Ethics Committee before the trial began,
306 and written informed consent was obtained from each subject.

307 **Blood sample collection for plasma PK and urea**

308 Blood samples (3 mL/timepoint) were obtained to determine drug and urea concentrations.
309 On the day of BAL procedure (Day 3 for Groups 1 and 2; Day 4 for Group 3), serial blood
310 samples for assay of plasma drug levels were taken before the final dose and 0.5, 1, 2, 3, 4,
311 6, 8, and 12 h post dose. For all groups, blood samples were also taken immediately before
312 the bronchoscopy (performed at 4–5 h or 11–12 h after final dose) for assay of BAL time-
313 matched plasma drug and urea levels. Blood samples were collected and immediately
314 placed on ice, and centrifuged at $1500 \times g$ for 10 min at 4°C. After centrifugation, the plasma
315 was divided into two aliquots and snap frozen on dry ice within 60 min of collection, then
316 stored at -80°C until analyzed. Analysis of AT-511 and metabolites was performed by
317 Altasciences Company, Inc (Laval, Quebec, Canada), and urea analysis was performed by
318 MicroConstants, Inc (San Diego, CA, USA).

319 **Bronchoscopy and BAL**

320 BAL samples were taken 4–5 h and 11–12 h after dosing on Day 3 (Groups 1 and 2) or Day 4
321 (Group 3). The subjects were prepared with 6% lidocaine gel for nasal local anesthesia and
322 lubrication. Midazolam 1 mg/mL with a 0.9% saline flush was prescribed for sedation if
323 needed. The saline for lavage was drawn up in four 50 mL aliquots for a total volume of 200
324 mL. Up to four or five BAL samples (BAL 1–5) were collected for each subject. BAL 1 was

325 processed alone, while BAL 2–4 (or BAL 2–5, if a fifth sample was collected) were pooled
326 together for processing. For each of the two resulting samples, 2 × 4 mL BAL fluid was sent
327 on ice to the laboratory for cell count and differential, while the remaining BAL fluid was
328 centrifuged at 400 × *g* for 5 min at 4°C to separate the BALF and pellet. From the BALF, 4 × 2
329 mL aliquots (two for urea and two for PK) were prepared in cryovials and frozen at -80°C.
330 The pellets (containing AM) were resuspended in ice cold 70% methanol solution containing
331 5 mM dibromoacetic acid and frozen on dry ice or at -80°C. The BALF and AM samples were
332 stored at -80°C until shipped, frozen and on dry ice. For the BALF samples, analysis of AT-
333 511 and AT-273 was performed by Altasciences Company, Inc (Laval, Quebec, Canada) and
334 urea analysis was performed by MicroConstants, Inc (San Diego, CA, USA). For the AM
335 samples, analysis of AT-9010 was performed by the University of Nebraska Medical Center
336 (Omaha, NE, USA).

337 **AT-511 and AT-273 plasma and BAL assays**

338 Concentrations of AT-511 and AT-273 measured in plasma and BAL supernatants were
339 determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) (Altasciences
340 Company, Inc). BAL samples were collected and mixed with an anti-adsorptive agent
341 solution prior to storage. Following deproteinization with cold acetonitrile and methanol
342 (1:3), samples were subsequently diluted for injection. Chromatographic separation
343 involved gradient elution on an XBridge C₁₈ column (50 × 4.6 mm, 3.5 μm) using 10 mM
344 ammonium bicarbonate and acetonitrile and methanol (1:1) as organic modifier. The LC
345 system was coupled to a SCIEX API 5000 mass spectrometer operated in positive
346 electrospray ionization mode monitoring the multiple reaction monitoring (MRM)
347 transitions 582.2>376.2 (AT-511) and 300.1>152.2 (AT-273). Analytical ranges were between

348 1 (LLQ) and 1000 ng/mL for both analytes in plasma, 0.200 (LLQ) and 200 ng/mL for AT-511,
349 and 0.400 (LLQ) and 400 ng/mL for AT-273 in BAL.

350 **AT-9010 assay**

351 Concentrations of AT-9010 in AM and other cell populations isolated from the upper airway
352 lavage fluid were determined by LC-MS/MS (University of Nebraska Medical Center). Briefly,
353 AT-9010 was extracted from cell debris via anion-exchange solid-phase extraction (SPE)
354 followed by dephosphorylation to AT-273 via acid phosphatase. AT-273 was desalted by a
355 reversed-phase SPE cartridge and analyzed using LC-MS/MS. Chromatographic separation
356 was carried out on a Synergi Polar-RP 100 × 2.00 mm column for the stationary phase, using
357 5% acetonitrile, 0.1% formic acid in water, with 0.1% formic acid in acetonitrile with
358 gradient elution for the mobile phase. AT-273 was detected by an AB Sciex 6500 triple
359 quadrupole mass spectrometer in positive ion mode monitoring MRM transition
360 300.0>152.1. The analytical range was from 3.34 (LLQ) to 3340 fmol/sample. A mean
361 alveolar macrophage cell volume of 2.42 μL/10⁶ cells was used in calculating AT-9010
362 concentrations (31).

363 **Urea plasma and BAL assays**

364 Plasma urea concentrations were measured using a colorimetric detection assay with an
365 assay range from 2.5 (LLQ) to 50 mg/dL. BAL urea concentrations were quantified using an
366 immunoassay with an assay range from 0.15 to 2.5 mg/dL using 150 μL of sample, and from
367 0.05 to 1 mg/dL using 300 μL of sample.

368 **Calculation of the volume of ELF and drug concentrations**

369 Drug levels in lung ELF were calculated by correcting for urea levels in the BAL and the
370 corresponding plasma samples as: $Conc_{ELF} = Conc_{BAL} \times (Urea_{plasma}/Urea_{BAL})$, where $Conc_{ELF}$

371 and Conc_{BAL} are drug levels in the ELF and BAL, respectively, and $\text{Urea}_{\text{plasma}}$ and Urea_{BAL} are
372 the plasma and BAL urea levels, respectively.

373 **PK analysis**

374 Plasma PK parameters were derived from plasma concentration data, using non-
375 compartmental analysis in WinNonLin v8.3. C_{max} , T_{max} , and C_{trough} were calculated directly
376 from the concentration–time data. AUC_t after the final dose was calculated using the
377 trapezoidal method. The PK concentration data were summarized using the PK
378 concentration population and PK parameters were summarized using the PK parameter
379 population. The pooled BAL 2–4 samples (or BAL 2–5, where a fifth BAL sample was
380 collected) were used for the ratios and summary statistics.

381 **Statistical analysis**

382 All statistical analyses were carried out using SAS[®] version 9.4. PK analysis was carried out
383 using non-compartmental approaches in WinNonlin version 8.3.

384 **Laboratory and safety assessment**

385 Safety was measured by clinical laboratory tests (hematology, biochemistry, coagulation,
386 serum chemistry, and urinalysis), physical examination, vital signs, 12-lead ECGs, spirometry,
387 SARS-CoV-2 testing, and monitoring of AEs. All AEs were coded using the Medical Dictionary
388 for Regulatory Activities (MedDRA) v24.1. Concomitant medications were coded using the
389 World Health Organization (WHO) Drug Global coding dictionary (September 2021 version).

390

391 **ACKNOWLEDGMENTS**

392 This study was funded by Atea Pharmaceuticals, Inc and F Hoffmann-LaRoche Ltd. Medical
393 writing support was provided by Samantha Brick, Elements Communications Ltd, UK, and
394 funded by Atea Pharmaceuticals, Inc.

395 Xiao-Jian Zhou, Arantxa Horga, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, and
396 Janet Hammond are employees of and may own stock in Atea Pharmaceuticals, Inc, Boston,
397 MA, USA; Adeep Puri is an employee of Hammersmith Medicines Research Ltd, London, UK,
398 which was contracted to help perform this research; Lee Winchester and Courtney V.

399 Fletcher are employees of the University of Nebraska Medical Center, Omaha, NE, USA, and
400 were contracted to help perform this research.

401 **REFERENCES**


- 402 1. Roque M, Proudfoot K, Mathys V, Yu S, Krieger N, Gernon T, Gokli K, Hamilton S, Cook C,
403 Fong Y. 2021. A review of nasopharyngeal swab and saliva tests for SARS-CoV-2
404 infection: Disease timelines, relative sensitivities, and test optimization. *J Surg Oncol*
405 124:465-475.
- 406 2. Candel S, Tyrkalska SD, Álvarez-Santacruz C, Mulero V. 2023. The nasopharyngeal
407 microbiome in COVID-19. *Emerg Microbes Infect* 12:e2165970.
- 408 3. Bösmüller H, Matter M, Fend F, Tzankov A. 2021. The pulmonary pathology of COVID-
409 19. *Virchows Arch* 478:137-150.
- 410 4. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M,
411 Hauptmann K, Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H,
412 Heppner FL, Horst D. 2021. Causes of death and comorbidities in hospitalized patients
413 with COVID-19. *Scientific Reports* 11:4263.
- 414 5. Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A, German P. 2020.
415 Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of
416 COVID-19, in Healthy Subjects. *Clin Transl Sci* 13:896-906.
- 417 6. Wang Z, Yang L, Song XQ. 2022. Oral GS-441524 derivatives: Next-generation inhibitors
418 of SARS-CoV-2 RNA-dependent RNA polymerase. *Front Immunol* 13:1015355.
- 419 7. Singh M, de Wit E. 2022. Antiviral agents for the treatment of COVID-19: Progress and
420 challenges. *Cell Rep Med* 3:100549.
- 421 8. Conti V, Sellitto C, Torsiello M, Manzo V, De Bellis E, Stefanelli B, Bertini N, Costantino
422 M, Maci C, Raschi E, Sabbatino F, Corbi G, Pagliano P, Filippelli A. 2022. Identification of



- 423 Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review. *JAMA*
424 *Network Open* 5:e227970-e227970.
- 425 9. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M,
426 Waters L, Burger D, Back DJ, Khoo S. 2022. Recommendations for the Management of
427 Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid)
428 and Comedications. *Clin Pharmacol Ther* 112:1191-1200.
- 429 10. Saravolatz LD, Depcinski S, Sharma M. 2023. Molnupiravir and Nirmatrelvir-Ritonavir:
430 Oral Coronavirus Disease 2019 Antiviral Drugs. *Clin Infect Dis* 76:165-171.
- 431 11. Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. 2023. The Antiviral
432 Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. *Viruses*
433 15:976.
- 434 12. Masyeni S, Iqhrammullah M, Frediansyah A, Nainu F, Tallei T, Emran TB, Ophinni Y,
435 Dhama K, Harapan H. 2022. Molnupiravir: A lethal mutagenic drug against rapidly
436 mutating severe acute respiratory syndrome coronavirus 2-A narrative review. *J Med*
437 *Virol* 94:3006-3016.
- 438 13. Waters MD, Warren S, Hughes C, Lewis P, Zhang F. 2022. Human genetic risk of
439 treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The
440 special case of molnupiravir. *Environ Mol Mutagen* 63:37-63.
- 441 14. Malin JJ, Weibel S, Gruell H, Kreuzberger N, Stegemann M, Skoetz N. 2023. Efficacy and
442 safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review
443 and meta-analysis. *Journal of Antimicrobial Chemotherapy* doi:10.1093/jac/dkad132.

- 444 15. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang
445 M, Mao Q. 2022. Efficacy and safety of three new oral antiviral treatment (molnupiravir,
446 fluvoxamine and Paxlovid) for COVID-19 : a meta-analysis. *Ann Med* 54:516-523.
- 447 16. Sanderson T, Hisner R, Donovan-Banfield Ia, Hartman H, Løchen A, Peacock TP, Ruis C.
448 2023. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
449 *Nature* doi:10.1038/s41586-023-06649-6.
- 450 17. Leegwater E, Moes D, Bosma LBE, Ottens TH, van der Meer IM, van Nieuwkoop C, Wilms
451 EB. 2022. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized
452 COVID-19 Patients. *Antimicrob Agents Chemother* 66:e0025422.
- 453 18. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut N, Morin MJ, Szewczyk LJ,
454 Painter GR. 2021. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a
455 Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. *Antimicrob*
456 *Agents Chemother* 65.
- 457 19. Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M,
458 Chan PLS, Demers N, Corrigan B, Damle B. 2022. Pharmacokinetics of Oral
459 Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With
460 Renal Impairment. *Clin Pharmacol Ther* 112:892-900.
- 461 20. Sahin G, Akbal-Dagistan O, Culha M, Erturk A, Basarir NS, Sancar S, Yildiz-Pekoz A. 2022.
462 Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19
463 Treatment. *J Pharm Sci* 111:2652-2661.
- 464 21. Wang Y, Chen L. 2020. Lung tissue distribution of drugs as a key factor for COVID-19
465 treatment. *British Journal of Pharmacology* 177:4995-4996.

- 466 22. Berliba E, Bogus M, Vanhoutte F, Berghmans PJ, Good SS, Moussa A, Pietropaolo K,
467 Murphy RL, Zhou XJ, Sommadossi JP. 2019. Safety, pharmacokinetics and antiviral
468 activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and
469 without cirrhosis. *Antimicrob Agents Chemother* 63.
- 470 23. Good SS, Moussa A, Zhou XJ, Pietropaolo K, Sommadossi JP. 2020. Preclinical evaluation
471 of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity
472 against hepatitis C virus. *PLoS One* 15:e0227104.
- 473 24. Good SS, Westover J, Jung KH, Zhou XJ, Moussa A, La Colla P, Collu G, Canard B,
474 Sommadossi JP. 2021. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a
475 Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of
476 COVID-19. *Antimicrob Agents Chemother* 65.
- 477 25. Shannon A, Fattorini V, Sama B, Selisko B, Feracci M, Falcou C, Gauffre P, El Kazzi P,
478 Delpal A, Decroly E, Alvarez K, Eydoux C, Guillemot J-C, Moussa A, Good SS, La Colla P,
479 Lin K, Sommadossi J-P, Zhu Y, Yan X, Shi H, Ferron F, Canard B. 2022. A dual mechanism
480 of action of AT-527 against SARS-CoV-2 polymerase. *Nature Communications* 13:621.
- 481 26. Zhou XJ, Horga A, Morelli G, Montrond M, Pietropaolo K, Belanger B, Good SS, Moussa
482 A, Hammond J, Sommadossi JP. 2021. High lung levels of active triphosphate predicted
483 with oral AT-527 in COVID patients. *Topics in Antiviral Medicine* 29:127.
- 484 27. Boffito M, Dolan E, Singh K, Holmes W, Wildum S, Horga A, Pietropaolo K, Zhou XJ,
485 Clinch B, Collinson N, Ukachukwu V. 2023. A Phase 2 Randomized Trial Evaluating the
486 Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory
487 Patients with Mild or Moderate COVID-19 (MOONSONG Study). *Microbiol Spectr*
488 doi:10.1128/spectrum.00077-23:e0007723.

- 489 28. Mungur O, Berliba E, Bourgeois S, Cardona M, Jucov A, Good S, Moussa A, Pietropaolo K,
490 Zhou X-J, Brown N. 2020. A combination of AT-527, a pan-genotypic guanosine
491 nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected
492 subjects. *Journal of Hepatology* 73:S357.
- 493 29. Horga A, Kuritzkes DR, Kowalczyk JJ, Pietropaolo K, Belanger B, Lin K, Perkins K,
494 Hammond J. 2023. Phase II study of bemnifosbuvir in high-risk participants in a hospital
495 setting with moderate COVID-19. *Future Virology* 18:489-500.
- 496 30. Horga A, Saenz R, Yilmaz G, Simón-Campos A, Pietropaolo K, Stubbings WJ, Collinson N,
497 Ishak L, Zrinscak B, Belanger B, Granier C, Lin K, C Hurt A, Zhou X-J, Wildum S, Hammond
498 J. Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19
499 in an outpatient setting (MORNINGSKY). *Future Virology* doi:10.2217/fvl-2023-0115.
- 500 31. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. 1990. Azithromycin
501 concentrations at the sites of pulmonary infection. *Eur Respir J* 3:886-90.
- 502





—●— 275 mg AT-527 [BID] (2.5 days) Day 3
- -■- - 550 mg AT-527 [BID] (2.5 days) Day 3
- -x- - 825 mg AT-527 [BID] (3.5 days) Day 4

